Loading
A phase 1/2 trial of ZG006 in small-cell lung cancer, run by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, now recruiting.
Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma is a phase 1/2 interventional study registered as NCT05978284 by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, with 54 participants planned, started 2023-10-27 and due to reach its primary completion in 2026-09. Interventions recorded: ZG006. Conditions listed: Small Cell Lung Cancer, Neuroendocrine Carcinoma. No results are recorded here; the registry entry is the source.
Shares ZG006, Suzhou Zelgen Biopharmaceuticals, Small-cell lung cancer.
Shares ZG006, Suzhou Zelgen Biopharmaceuticals, Small-cell lung cancer.
Shares ZG006, Suzhou Zelgen Biopharmaceuticals.
Shares ZG006, Suzhou Zelgen Biopharmaceuticals.
Shares ZG006, Suzhou Zelgen Biopharmaceuticals.